- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT00973700
Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Children, Adolescents and Adults (3 to 64 Years)
A Randomized, Open Label, Single Center, Dose- and Regimen-Ranging Study to Evaluate Immunogenicity, Safety and Tolerability of Different Formulations of an Adjuvanted and Non-Adjuvanted Egg-Derived, Inactivated Novel Swine Origin A/H1N1 Monovalent Subunit Influenza Virus Vaccine in Healthy Children and Adults Ages 3 to 64 Years
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Faktiske)
Fase
- Fase 3
Kontakter og plasseringer
Studiesteder
-
-
-
San Jose, Costa Rica
- Instituto de Atencion Pediatrica, Avenida 0-2 Calle 22, Paseo Colon del Restaurante La, Bastilla 50 metros Sur, Edificio 5.
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Children, adolescents, and adults 3 to 64 years of age in good health as determined by medical history, physical assessment and clinical judgement of the investigator and without influenza within the past 6 months.
Exclusion Criteria:
- History of serious disease.
- History of serious reaction following administration of vaccine or hypersensitivity to vaccine components.
- Known or suspected impairment/alteration of immune function.
- Receipt or planned receipt of seasonal trivalent influenza vaccine within 1 week before or after each study vaccination.
For additional entry criteria, please refer to protocol.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Forebygging
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: 2x7.5adj
Two doses of MF59 adjuvanted (adj) A/H1N1
|
MF59 adjuvanted (adj) egg-derived A/H1N1 with traces of Thiomersal
|
Eksperimentell: 7.5adj_1_8
MF59 adjuvanted (adj) A/H1N1 on days 1 and 8
|
MF59 adjuvanted (adj) egg-derived A/H1N1 with traces of Thiomersal
|
Eksperimentell: 7.5adj_1_22
MF59 adjuvanted (adj) A/H1N1 on study days 1 and 22
|
MF59 adjuvanted (adj) egg-derived A/H1N1 with traces of Thiomersal
|
Eksperimentell: 15_1_22
A/H1N1 on study days 1 and 22
|
Unadjuvanted egg-derived A/H1N1 with traces of Thiomersal
|
Eksperimentell: 2x15_1_22
Two doses of A/H1N1 (one in each arm) on study days 1 and 22
|
Unadjuvanted egg-derived A/H1N1 with traces of Thiomersal
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Percentage of Subjects With Seroconversion and HI Titer ≥1:40 in Children 3 to 17 Years of Age
Tidsramme: Day 1 to day 387
|
Seroconversion: The percentage of subjects with either a pre-vaccination HI titer < 1:10 and a post-vaccination HI titer >1:40 or a prevaccination HI titer >1:10 and a minimum four-fold rise in post-vaccination HI antibody titer. The analyses were performed on the Per-Protocol Set (PPS). |
Day 1 to day 387
|
Percentage of Subjects With Seroconversion and HI Titer ≥ 1:40 in Adults 18 to 64 Years of Age
Tidsramme: Day 1 to day 387
|
Seroconversion: The percentage of subjects with either a pre-vaccination HI titer < 1:10 and a post-vaccination HI titer >1:40 or a prevaccination HI titer >1:10 and a minimum four-fold rise in post-vaccination HI antibody titer. Analyses were performed on the Per-Protocol set (PPS). |
Day 1 to day 387
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Age Distribution at Baseline
Tidsramme: Baseline
|
Baseline
|
|
Percentage of Subjects With Seroconversion and HI Titer ≥1:40, in 3 to <9 Years and 9 to 17 Years
Tidsramme: Day 1 to day 387
|
Seroconversion: The percentage of subjects with either a pre-vaccination HI titer < 1:10 and a post-vaccination HI titer >1:40 or a prevaccination HI titer >1:10 and a minimum four-fold rise in post-vaccination HI antibody titer. The analyses were performed on the Per-Protocol Set (PPS). |
Day 1 to day 387
|
HI GMRs, in 3 to <9 Years and 9 to 17 Years
Tidsramme: Day 1 to day 387
|
Geometric Mean Ratios (GMRs) of hemagglutination inhibition (HI) antibody assay (ratio of post-vaccination versus pre-vaccination HI titers). The analyses were performed on the the per-protocol set (PPS). |
Day 1 to day 387
|
HI GMR, in Adults 18 to 64 Years
Tidsramme: Day 1 to day 387
|
Geometric Mean Ratios (GMRs) of hemagglutination inhibition (HI) antibody assay (ratio of post-vaccination versus pre-vaccination HI titers). The analyses were performed on the Per-Protocol Set (PPS). |
Day 1 to day 387
|
Percentage of Subjects With Seroconversion and HI Titer ≥1:40, in Adults 18 to 64 Years
Tidsramme: 7 days and 21 days after each vaccination
|
Seroconversion: The percentage of subjects with either a pre-vaccination HI titer < 1:10 and a post-vaccination HI titer >1:40 or a prevaccination HI titer >1:10 and a minimum four-fold rise in post-vaccination HI antibody titer. The analyses were performed on the per-protocol set (PPS). |
7 days and 21 days after each vaccination
|
Number of Subjects With at Least One Reactogenicity Sign, in 3 to <9 Years of Age
Tidsramme: 7 days after each vaccination
|
Number of subjects with specified solicited local and systemic reactions in adult subjects (3 to <9 years of age). Postvac: postvaccination; Analges: analgesics; Antipyr: antipyretics. The analyses were performed on the safety set. Note: 1) postvac 1 = after the first vaccination and 2) postvac 2 = after the second vaccination |
7 days after each vaccination
|
Number of Subjects With at Least One Reactogenicity Sign, in 9 to 17 Years of Age
Tidsramme: 7 days after each vaccination
|
Number of subjects with specified solicited local and systemic reactions in adult subjects (9 to 17 years of age). Postvac: postvaccination Analges: analgesics Antipyr: antipyretics The analyses were performed on the safety set. Note: 1) postvac 1 = after the first vaccination and 2) postvac 2 = after the second vaccination. |
7 days after each vaccination
|
Number of Subjects With at Least One Reactogenicity Sign, in 18 to 64 Years of Age
Tidsramme: 7 days after each vaccination
|
Number of subjects with specified solicited local and systemic reactions in adult subjects (18 to 64 years of age). Note: 1) postvac. 1 = after the first vaccination and 2) postvac. 2 = after the second vaccination. The analyses were performed on the safety set. |
7 days after each vaccination
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studieleder: Novartis Vaccines, Novartis Vaccines
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- V112_04
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Roman 2009 Influensa H1N1
-
The University of Hong KongQueen Elizabeth Hospital, Hong Kong; Queen Mary Hospital, Hong Kong; Pamela... og andre samarbeidspartnereFullført
-
University of RochesterNational Institutes of Health (NIH)Tilbaketrukket2009 H1N1 influensaForente stater
-
University of RochesterNational Institutes of Health (NIH)Fullført
-
David ScheifeleCanadian Institutes of Health Research (CIHR); PHAC/CIHR Influenza Research...FullførtH1N1/2009 InfluensaCanada
-
Fluart Innovative Vaccine Ltd, HungaryFullførtInfluensa, menneske | Roman 2009 Influensa H1N1Ungarn
Kliniske studier på MF59-eH1N1_f
-
SeqirusNovartis VaccinesFullført
-
SeqirusDepartment of Health and Human ServicesRekrutteringInfeksjoner | Virussykdommer | Luftveisinfeksjoner | Influensa, menneske | Infeksjon ViralFilippinene, Forente stater
-
Novartis VaccinesFullført
-
Sanofi Pasteur, a Sanofi CompanyFullførtInfluensa | Friske FrivilligeForente stater
-
The University of QueenslandSyneos Health; Coalition for Epidemic Preparedness InnovationsFullførtCovid-19 | SARS-CoV-2Australia
-
Novartis VaccinesFullførtInfluensaForente stater, Mexico
-
HIV Vaccine Trials NetworkSouth Africa AIDS Vaccine InitiativeFullførtHIV-seronegativitet | HIV-forebyggende vaksineSør-Afrika
-
National Institute of Allergy and Infectious Diseases...GlaxoSmithKline; Bill and Melinda Gates Foundation; Medical Research Council og andre samarbeidspartnereFullført
-
National Institute of Allergy and Infectious Diseases...Novartis Vaccines; HIV Vaccine Trials Network; IPPOX FoundationFullførtHIV-infeksjonerSør-Afrika, Zambia, Tanzania
-
Novartis VaccinesFullført